A Phase 1 exercise dose escalation study for stroke survivors with impaired walking

Publisher： John Wiley & Sons Inc

E-ISSN： 1747-4949|10|7|1051-1056

ISSN： 1747-4930

Source： INTERNATIONAL JOURNAL OF STROKE, Vol.10, Iss.7, 2015-10, pp. : 1051-1056

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase 1 dose‐escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 902-904

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 1, open‐label, dose escalation, safety, and pharmacokinetics study of ME‐344 as a single agent in patients with refractory solid tumors

By  

CANCER, Vol. 121, Iss. 7, 2015-04 ,pp. : 1056-1063

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I Dose Escalation Study of Carboplatin to a Fixed Dose of Irinotecan as First-Line Treatment of Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 280-284

Karger

Access to resources Recommend Favorite

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 1b, multicenter, single blinded, placebo‐controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4268-4276

John Wiley & Sons Inc

Access to resources Recommend Favorite